Medicare drug price negotiation became law on 1 January 2026. For the first time in the programme’s 60-year history, the federal government set binding price caps on ten of the most widely prescribed medicines in the United States, ending a legal arrangement that had kept American patients paying the highest drug prices of any developed nation. The results are instructive, and not entirely in the direction the most alarmed pharmaceutical executives predicted.
The Inflation Reduction Act of 2022 stripped the “non-interference” clause that had stopped the Centres for Medicare and Medicaid Services from bargaining directly with drugmakers. What followed was a three-year confrontation, legal, political, and commercial, that ended with Maximum Fair Prices taking effect across ten blockbuster medications. The first negotiation cycle is settled. The question is what it reveals about the cycles that follow.
What Is Medicare Drug Price Negotiation and Why Does It Matter?
Medicare is the largest single drug purchaser in the United States, covering roughly 67 million beneficiaries. Before the IRA, it was the only major national health programme in a developed country legally barred from negotiating prices. Private insurers, the Department of Veterans Affairs, and every European government already did what Medicare could not. The non-interference clause, inserted into the 2003 legislation that created Medicare Part D, was a concession to the pharmaceutical industry at the public’s expense.
The IRA corrected that in 2022. Under the new framework, CMS can designate drugs with no generic or biosimilar competition that rank among the highest spenders under Part D or Part B. Manufacturers that refuse to participate or reject the final Maximum Fair Price face an excise tax starting at 65% of gross sales and rising to 95%, a penalty that makes non-compliance commercially untenable. The programme targets monopoly-stage drugs, not newly launched medicines. It is not a blanket price control but a narrowly defined mechanism aimed at the most mature, least contested corner of the pharmaceutical market.
The First Medicare Negotiated Drug Prices Explained
Which Drugs Were Selected for Negotiation?
The first ten medications selected included Eliquis and Xarelto, the dominant oral anticoagulants; Jardiance, Farxiga, and Januvia, used for diabetes and heart failure; Entresto for heart failure; the rheumatoid arthritis biologics Enbrel and Stelara; Imbruvica for blood cancers; and Fiasp/NovoLog for insulin. Together they accounted for roughly $50 billion in annual Medicare Part D spending. All met the statutory test: on the market for at least seven years as small molecules or eleven years as biologics, with no FDA-approved generic or biosimilar competitor at the time of selection.
The table below shows each drug, its therapeutic area, manufacturer, and approximate list price discount under the negotiated MFP.
| Drug | Therapeutic Area | Manufacturer | List Price Discount |
|---|---|---|---|
| Januvia | Diabetes | Merck | ~79% |
| Farxiga | Diabetes / Heart Failure | AstraZeneca | ~68% |
| Enbrel | Rheumatoid Arthritis | Amgen | ~67% |
| Stelara | Immunology / RA | Johnson and Johnson | ~66% |
| Jardiance | Diabetes / Heart Failure | Boehringer / Lilly | ~66% |
| Xarelto | Anticoagulant | Johnson and Johnson | ~62% |
| Eliquis | Anticoagulant | Bristol Myers Squibb / Pfizer | ~56% |
| Entresto | Heart Failure | Novartis | ~53% |
| Imbruvica | Blood Cancers | AbbVie / Johnson and Johnson | ~38% |
| Fiasp / NovoLog | Diabetes (Insulin) | Novo Nordisk | Capped at $35/month (IRA) |
How Medicare Determines Negotiated Prices
CMS issues an initial Maximum Fair Price offer, drawing on the drug’s therapeutic value relative to cheaper alternatives, disclosed research and development costs, any federal funding received during development, and unit manufacturing expenses. Manufacturers submit data-backed counteroffers and attend structured negotiation meetings. The MFP is capped at a percentage of the non-federal average manufacturer price, ranging from 40% to 75%, depending on how long the drug has been on the market. Longer-established drugs face steeper ceilings. No company successfully exited the process after federal courts dismissed constitutional challenges in 2023 and 2024.
Medicare Negotiated Prices vs List Prices
Average Discount Levels Across Negotiated Drugs
The headline figures are striking. Merck’s Januvia saw its negotiated price set 79% below the published list price. Enbrel and Stelara, both biologics commanding annual list prices in the range of $60,000 to $80,000, saw discounts of 67% and 66% respectively. At the other end, Imbruvica, a blood cancer treatment, received the smallest reduction at roughly 38% off list price.
Those headline percentages need context. List prices in the American pharmaceutical market are not what anyone actually pays. They are the Wholesale Acquisition Cost, kept high to accommodate the confidential rebates that pharmacy benefit managers extract from manufacturers in exchange for formulary placement. The gap between list and net in mature branded drugs frequently exceeds 50%.
Medicare Part D legislation explicitly bars CMS from negotiating drug prices. Pharmaceutical industry lobbying ensures the clause is written into the founding statute.
IRA repeals the non-interference clause and authorises CMS to negotiate Maximum Fair Prices on high-expenditure, single-source drugs.
CMS designates the first negotiation cohort. Federal courts dismiss constitutional challenges from multiple major manufacturers.
CMS publishes the finalised MFPs for all ten drugs. Discounts range from 38% to 79% off list price. Markets respond with mild relief rallies on affected stocks.
First negotiated prices apply at the pharmacy counter for Medicare Part D beneficiaries. $2,100 annual out-of-pocket cap also activates.
15 additional Part D drugs (including GLP-1s) for 2027; Part B infusions from 2028; 20 drugs annually from 2029 onward.
Why List Prices Often Differ from Actual Drug Costs
CMS was already receiving statutory discounts before the IRA took effect. When the negotiated MFPs are measured against net prices Medicare actually paid, the incremental savings figure drops to an estimated 22%. That number better reflects the true fiscal impact. Applied across $50 billion in annual spending, a 22% net reduction works out to roughly $6 billion in annual programme savings. Not negligible, but far removed from the 79% figures that dominate the policy communications.
Winners and Losers from the First Negotiation Results
Benefits for Medicare Beneficiaries
Seniors whose plans required co-insurance payments based on a percentage of the drug’s price see direct reductions, because the base price has fallen. The first negotiation cycle also runs alongside the IRA’s out-of-pocket cap, which set a $2,100 annual maximum for Medicare Part D beneficiaries in 2026. For patients on Eliquis or Entresto, monthly co-pays that previously ran well into the hundreds of dollars have come down. Lower costs reduce the cost-related non-adherence that has long produced secondary hospitalisations in chronic disease management.
Impact on Government Healthcare Spending
The savings compound as subsequent rounds take effect: 15 additional Part D drugs entered negotiation for 2027, drawing in GLP-1 agonists including Ozempic. The third cycle extends the programme to Medicare Part B, covering physician-administered drugs. The law mandates 15 drugs for 2027, 15 for 2028, then 20 annually from 2029. The savings trajectory is a slope, not a cliff.
Challenges for Pharmaceutical Companies
For the companies directly affected, the first cycle confirmed what their models had projected since 2022. Bristol Myers Squibb faces a durable reduction on Eliquis, its most profitable product. Merck loses the high-margin tail of Januvia. Johnson and Johnson absorbs a steep cut on Stelara at the very moment biosimilar competition was already compressing its pricing power.
The legal strategy failed. Federal courts upheld the programme’s constitutionality in every significant challenge. What remains for manufacturers is operational adjustment: cutting commercial infrastructure around affected products, redirecting capital toward newer assets, and managing the earnings impact through cost reductions.
How Drug Price Negotiation Changes the Pharmaceutical Business Model
The Shift Away from Unlimited Pricing Power
The pre-IRA model rewarded patience. A company that launched a drug, secured a strong market position, and raised prices 7% to 9% annually across a 15-to-20-year exclusivity window could extract several times the original launch-year revenue from the same molecule. That model is over for any drug that reaches the Medicare expenditure thresholds. The IRA imposes hard profit windows: nine years for small molecules, thirteen for biologics, after which the government can cap the price regardless of remaining patent life.
Changes in Drug Development Incentives
The four-year gap in negotiation eligibility between pills and biologics has produced a visible shift in capital allocation. Venture funds are applying higher hurdle rates to small-molecule programmes. The IRA’s exemption for orphan drugs approved for a single rare disease has generated the predictable response: clinical programmes are clustering around narrow indications rather than broad public health applications. Better returns per programme, fewer medicines for common diseases.
Pipeline pruning has followed. Companies are cancelling secondary indication expansions because the negotiation clock starts at initial FDA approval. A cancer drug approved in 2020 that would have been expanded to a second tumour type in 2025 is being left with its original label, because the company cannot afford to spend on a new indication arriving just before the negotiation window opens.
Lifecycle Management Strategies
Manufacturers are responding to the shortened profit window by raising initial launch prices. If nine years rather than twenty is the effective commercial horizon, revenue needs to be front-loaded. New drugs entering the market in 2024 and 2025 are launching at prices 30% to 50% higher than comparable products launched a decade earlier. The IRA was designed to reduce drug costs. Its structural incentives are producing higher launch prices on the next generation of medicines while reducing prices on the current one.
Pharmaceutical Stock Impact: What Investors Need to Know
Which Drugmakers Face the Greatest Exposure?
The highest-risk profiles belong to companies with concentrated revenue in cardiovascular, metabolic, and age-related disease categories where Medicare is a large share of the patient population. Bristol Myers Squibb, Pfizer, Merck, Johnson and Johnson, and AstraZeneca all carry products either already negotiated or approaching eligibility in the next two cycles. Mid-cap biotechs where a single asset accounts for more than 15% of net revenue are more exposed than diversified companies, which can absorb one MFP haircut while growing elsewhere.
Market Reaction to Negotiation Results
The pharmaceutical sector did not collapse when the 2026 MFPs took effect. Markets had four years to price the legislation, and the final negotiated discounts came in below the worst-case scenarios modelled in 2022 and 2023. Several stocks registered mild relief rallies in September 2025 when final MFPs were announced. The “50% net revenue destruction” thesis from early IRA commentary has given way to a “22% incremental net haircut” consensus that translates into meaningful but workable EPS compression for most affected companies.
Investors evaluating pharmaceutical companies in this environment are better served by a stock-by-stock framework than by sector-level calls. For a structured approach to that kind of analysis, the 9-step stock analysis checklist for serious investors provides a systematic method for assessing revenue concentration risk alongside pipeline quality and balance sheet positioning.
Key Valuation Metrics to Monitor
The central metric for any pharmaceutical holding is now its IRA exposure figure: what percentage of total portfolio revenue comes from drugs approaching a CMS negotiation cycle. A company where 30% of revenue sits in products entering the nine-year or thirteen-year window within the next three years faces a very different earnings trajectory than one whose blockbusters were launched recently. Beyond revenue at risk, pipeline velocity matters: can new Phase III assets reach commercialisation fast enough to replace revenue from negotiated products?
The table below outlines the five metrics most relevant to evaluating pharma stocks under the IRA pricing regime.
| Metric | What to Measure | Why It Matters |
|---|---|---|
| IRA Exposure % | Revenue from drugs within 3 years of the 9/13-year window | Quantifies near-term top-line risk from MFP implementation |
| Pipeline Velocity | Number of Phase III assets and projected launch dates | Indicates capacity to replace revenue from negotiated products |
| Single-Asset Concentration | Revenue % from a single negotiated product | Mid-caps with one blockbuster face existential valuation risk |
| Geographic Revenue Mix | Non-US revenue as a share of total net revenue | Global diversification offsets domestic MFP margin compression |
| R&D Pipeline Mix | Share of pipeline in biologics, cell/gene therapy vs small molecules | Biologics carry 4-year longer pricing protection under IRA rules |
The Long-Term Impact on the Pharmaceutical Industry
Future Rounds of Medicare Negotiations
The second round brought GLP-1 agonists into the programme. Ozempic’s inclusion in the 2027 negotiation cycle has drawn more attention than any other pharmaceutical policy event since the IRA’s passage, both for its fiscal scale and for what it signals about CMS’s appetite to target the industry’s fastest-growing product class. The third round extended negotiations to Part B drugs, pulling in oncology infusions that had previously operated under different pricing dynamics.
Industry Adaptation Strategies
Large companies are running three broad responses. They are buying de-risked late-stage biotech assets with fresh, unnegotiated commercial histories. They are pushing harder for market share in Europe, China, and Japan to offset domestic margin compression. And they are shifting capital toward complex biologics, cell therapies, and gene therapies where the thirteen-year protection window is longer and biosimilar manufacturing barriers are much higher.
Potential Regulatory and Political Risks
How long the programme survives in its current form depends partly on who controls Washington. Proposals to shorten the biologics window from thirteen to nine years have attracted legislative support. Others want to expand the annual drug count from 20 to more than 50. A change in CMS leadership can alter enforcement intensity without new legislation. Several states are pursuing independent prescription drug affordability boards that could layer additional price controls on top of the federal programme. The direction of travel is clear enough.
What Healthcare Investors Should Watch Next
The annual CMS announcement each September identifying the next round of targeted drugs is the sector’s most important regulatory calendar event. Each list reshapes analyst models, corporate guidance, and acquisition pricing for the assets caught in the next cycle. Watching whether realised MFPs in subsequent rounds come in above or below the first cycle’s effective discounts will show whether CMS is becoming more aggressive. The GLP-1 cycle will answer that.
Key Takeaways from the First Medicare Drug Price Negotiation Results
The first cycle of Medicare drug price negotiation produced a manageable headwind rather than a structural collapse. The 79% headline discount on Januvia is real for patients paying co-insurance. The hit to corporate earnings is closer to 22% of net revenue on affected products. Both figures are true because the rebate architecture separates list prices from what buyers actually pay.
The business model is shifting. Shorter profit windows are producing higher launch prices, narrower indication strategies, and faster consolidation. Investors who apply broad sector discount factors are missing the real picture: exposure is asset-specific, pipeline-dependent, and cycle-by-cycle. The companies that arrive at each September announcement with clean IRA exposure metrics and credible revenue replacement plans will pull ahead. The others will not.
For patients, the shift delivers lower costs now. For the Treasury, the savings are growing. For the industry, what has happened so far is the easy part.